Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said that that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending Stelara or ustekinumab's marketing authorization in the European Union for the treatment of adult patients with moderately to severely active ulcerative colitis or UC.
from RTT - Biotech https://ift.tt/2yehhxa
via IFTTT
No comments:
Post a Comment